Information Provided By:
Fly News Breaks for February 12, 2020
Feb 12, 2020 | 17:54 EDT
Goldman Sachs analyst Amit Hazan initiated coverage of Varian Medical with a Buy rating and $171 price target. The analyst notes that in spite of the volatility created by the uneven quarterly execution, he sees medium term investment story for the stock as "healthier than it has been in years". Hazan adds that Varian's multiple new product and geographic opportunities are driving "excellent" top line visibility, and that its efforts to diversify sales are "still underappreciated".
News For VAR From the Last 2 Days
There are no results for your query VAR